Trial site
NRC Research Institute
Orange, California 92868, United StatesNot linked to an institution yet
- 12running trials
- 15closed trials
The trials here
What the 27 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 210 trials
- Phase 2/32 trials
- Status
- Completed12 trials
- Recruiting8 trials
- Active, not recruiting4 trials
- Terminated3 trials
- Lead sponsor
- Biohaven Therapeutics Ltd.4 trials
- Biohaven Pharmaceuticals, Inc.3 trials
- Xenon Pharmaceuticals Inc.3 trials
- Boehringer Ingelheim2 trials
- Bristol-Myers Squibb2 trials
- and 10 more
Running trials
Recruiting
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
NCT07686263· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Tony Ortiz, Site 0151
Recruiting
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
NCT07573176· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.
NCT07494305· Phase 2· LB Pharmaceuticals Inc.· Source
Contact: Abigail Parera
Recruiting
Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder
NCT07226661· Phase 2· Supernus Pharmaceuticals, Inc.· Source
Contact: Gianpiera Ceresoli-Borroni, PhD
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397· Phase 3· Cybin IRL Limited· Source
Contact: Christian Ortiz
Recruiting
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
NCT07140913· Phase 3· Bristol-Myers Squibb· Source
Contact: Tony Ortiz, Site 0148
Active, not recruiting
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
NCT07172516· Phase 3· Xenon Pharmaceuticals Inc.· Source
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273· Phase 3· Bristol-Myers Squibb· Source
Contact: Tony Ortiz, Site 0039
Active, not recruiting
An Open-Label Study of Azetukalner in Major Depressive Disorder
NCT06922110· Phase 3· Xenon Pharmaceuticals Inc.· Source
Active, not recruiting
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
NCT06775379· Phase 3· Xenon Pharmaceuticals Inc.· Source
Recruiting
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383· Phase 2· Intra-Cellular Therapies, Inc.· Source
Active, not recruiting
ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)
NCT05889273· Phase 2· MapLight Therapeutics· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
NCT06791122· Boehringer Ingelheim· Source
Completed
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)
NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source
Terminated
BHV-7000 Open-Label Extension Bipolar Mania Study
NCT06423794· Phase 2· Biohaven Therapeutics Ltd.· Source
Completed
BHV-7000 Acute Treatment of Bipolar Mania
NCT06419582· Phase 2/3· Biohaven Therapeutics Ltd.· Source
Completed
Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression
NCT06419608· Phase 2· Biohaven Therapeutics Ltd.· Source
Completed
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
NCT06126497· Phase 2· Suven Life Sciences Limited· Source
Completed
ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)
NCT05081245· Phase 2· MapLight Therapeutics· Source
Completed
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
NCT05279313· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Completed
A Study of JZP150 in Adults With Posttraumatic Stress Disorder
NCT05178316· Phase 2· Jazz Pharmaceuticals· Source
Completed
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)
NCT04846881· Phase 3· Boehringer Ingelheim· Source
Completed
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)
NCT04820309· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Terminated
Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
NCT04708834· Phase 3· Biohaven Pharmaceuticals, Inc.· Source
Completed
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
NCT04641143· Phase 3· Biohaven Pharmaceuticals, Inc.· Source
Completed
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
NCT03299166· Phase 2/3· Biohaven Pharmaceuticals, Inc.· Source
Terminated
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
NCT02446132· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Report an error